Viridian Therapeutics, Inc.\DEVRDN
Market cap
$2.6B
P/E ratio
| 2014/12 | 2015/12 | 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | |
| Depreciation & amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Stock-based compensation | 4 | 3 | 2 | 2 | 4 | 4 | 4 | 14 | 20 | 67 | 42 |
| Cash from operations | -2 | -7 | -7 | -28 | -27 | -36 | -30 | -55 | -94 | -184 | -232 |
| Capital expenditures | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -1 | -1 | -1 |
| Cash from investing | -0 | -0 | -0 | 1 | -30 | 28 | -50 | -74 | -115 | -94 | -229 |
| Repurchases of common stock | - | - | 0 | - | - | - | - | - | - | - | - |
| Cash from financing | 7 | 13 | -0 | 52 | 42 | 0 | 101 | 125 | 322 | 226 | 458 |
| Free cash flow | |||||||||||
| FCF margin (%) |